Serial Changes in Platelet Activation in Patients After Ischemic Stroke

Author:

Yip Hon-Kan1,Chen Shun-Sheng1,Liu Josef S.1,Chang Hsueh-Wen1,Kao Yi-Fen1,Lan Min-Yu1,Chang Yung-Yee1,Lai Shung-Lon1,Chen Wei-Hsi1,Chen Mien-Cheng1

Affiliation:

1. From the Division of Cardiology (H.-K.Y., M.-C.C.), Department of Neurology (J.S.L., Y.-F.K., M.-Y.L., Y.-Y.C., S.-L.L., W.-H.C.), Chang Gung Memorial Hospital, Kaohsiung; Department of Biological Sciences (S.-S.C., H.-W.C.), National Sun Yat-Sen University, Taiwan, Republic of China.

Abstract

Background and Purpose— Enhanced platelet activity has previously been reported in the acute phase after ischemic stroke. We tested the hypothesis that activated platelets (expressed by CD62p) are substantially increased in the acute stage after a stroke and decrease thereafter, and that antiplatelet therapies can suppress CD62p expression. Methods— We serially examined platelet CD62p expression using flow cytometry after acute ischemic stroke in 87 consecutive patients. The CD62p expression was also evaluated in 20 healthy volunteers and 33 at-risk control subjects. Results— CD62p expression was significantly higher in the acute phase after ischemic stroke than in normal and at-risk control subjects (both P <0.0001). CD62p expression decreased to a significantly lower level on day 21, and to a substantially lower level on day 90. CD62p expression was not significantly suppressed by warfarin. However, CD62p expression was significantly suppressed by aspirin treatment ( P =0.024) and more substantially suppressed by clopidogrel ( P <0.0001) on day 90. Furthermore, only clopidogrel treatment ( P =0.0016) was significantly independently associated with decreased CD62p expression on day 90. Conclusions— Platelet activation was significantly increased in acute ischemic stroke and substantially decreased thereafter. The lesser long-term pharmacodynamic potency of aspirin relative to clopidogrel raises the prospect of the need for more effective antiplatelet agents or a synergistic combination therapy for stroke prevention in the future.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3